A report examines the controversial FDA approval of aducanumab for Alzheimer’s disease
The journal report was released in Annals of Internal Medicine.
Experimental Alzheimer’s drug aducanumab is rejected by an FDA panel
The experimental treatment is theorized to clear clumps of the protein beta-amyloid…